Document Detail

Inhibition of calcium oxalate urolithiasis in a rat model of lithogenesis using bisphosphonates.
MedLine Citation:
PMID:  9048290     Owner:  NLM     Status:  MEDLINE    
Bisphosphonates bind renal calculi and inhibit calcium oxalate crystal growth in vitro. We evaluated their ability to inhibit calcium oxalate urolithiasis in a lithogenic rat model. Male Sprague-Dawley rats (four groups, eight rats each) were fed 1.0% ethylene glycol in their drinking water for 6 weeks. All rats had implantation of a 50- to 60-mg zinc pellet in their urinary bladder at the beginning of the 6-week period. The control group received no treatment. The other three groups received six weekly intraperitoneal injections of one of three bisphosphonates: pamidronate (APD), clodronate (CLO), or methylene diphosphonate (MDP). At the end of 6 weeks, the zinc pellet was retrieved and weighed; the kidneys were sectioned and stained to evaluate inflammation, tubular dilation, and crystal deposition; and blood and urine samples were analyzed for calcium and creatinine. There were no detectable biochemical differences between the control and the treatment groups. Zinc pellets removed from control animals had a significantly greater increase in weight secondary to crystal deposition than those from the treatment groups (mean 28.4% for control v 18.9%, 15.3%, and 18.6%, respectively, for animals given APD, CLO, and MDP). The control animals also had significantly higher scores for inflammation, tubular dilation, and crystal deposition than animals treated with MDP and CLO. Older and newer-generation bisphosphonates have an inhibitory effect on calcium oxalate urolithiasis that is demonstrable at relatively infrequent dosing intervals in vivo. More frequent dosing or higher doses may allow greater inhibition of stone formation.
M Gupta; O L Tuncay; E Valderrama; A D Smith
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of endourology / Endourological Society     Volume:  11     ISSN:  0892-7790     ISO Abbreviation:  J. Endourol.     Publication Date:  1997 Feb 
Date Detail:
Created Date:  1997-05-15     Completed Date:  1997-05-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8807503     Medline TA:  J Endourol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  IM    
Department of Urology, Long Island Jewish Medical Center, New Hyde Park, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analgesics, Non-Narcotic / administration & dosage,  pharmacology,  therapeutic use
Calcium / blood,  urine
Calcium Oxalate / antagonists & inhibitors*
Clodronic Acid / administration & dosage,  pharmacology*,  therapeutic use
Creatinine / blood,  urine
Diphosphonates / administration & dosage,  pharmacology*,  therapeutic use
Disease Models, Animal*
Dose-Response Relationship, Drug
Follow-Up Studies
Injections, Intraperitoneal
Rats, Sprague-Dawley
Urinary Bladder Calculi / chemically induced,  drug therapy*,  metabolism
Reg. No./Substance:
0/Analgesics, Non-Narcotic; 0/Diphosphonates; 10596-23-3/Clodronic Acid; 1984-15-2/methylene diphosphonate; 25454-23-3/Calcium Oxalate; 40391-99-9/pamidronate; 60-27-5/Creatinine; 7440-66-6/Zinc; 7440-70-2/Calcium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Noninvasive method for measuring thrombus formation in patients after peripheral angioplasty using t...
Next Document:  Evaluation of Doppler ultrasonography and dynamic contrast-enhanced CT in acute and chronic renal ob...